Prognostic factors for response to sildenafil in patients with erectile dysfunction

DOI: 10.1159/000049850
European Urology, 2001, 40, 641-6; discussion 647.

#	Paper	IF	Citations
78	A 4-year update on the safety of sildenafil citrate (Viagra). *Urology*, **2002**, 60, 67-90	1.6	188
77	Effect of sildenafil on nocturnal erections of potent men. *International Journal of Impotence Research*, **2003**, 15, 117-21	2.3	18
76	Hypogonadism and erectile dysfunction: the role for testosterone therapy. *International Journal of Impotence Research*, **2003**, 15 Suppl 4, S9-13	2.3	42
75	What to learn about sildenafil in the treatment of erectile dysfunction from 3-year clinical experience. *International Journal of Impotence Research*, **2003**, 15, 412-7	2.3	23
74	Deciphering erectile dysfunction drug trials. *Journal of Urology*, **2003**, 170, 353-8	2.5	49
73	Erectile dysfunction in the elderly: epidemiology, etiology and approaches to treatment. *Journal of Urology*, **2003**, 169, 1999-2007	2.5	82
72	Diabetes impairs endothelium-dependent relaxation of human penile vascular tissues mediated by NO and EDHF. *Biochemical and Biophysical Research Communications*, **2003**, 312, 1202-8	3.4	89
71	Sildenafil in erectile dysfunction: a critical review. *Current Medical Research and Opinion*, **2003**, 19, 241-62	2.5	77
70	A multicenter, randomized, double-blind, crossover study of patient preference for tadalafil 20 mg or sildenafil citrate 50 mg during initiation of treatment for erectile dysfunction. *Clinical Therapeutics*, **2003**, 25, 2709-23	3.5	82
69	Erectile Dysfunction in the Elderly: Epidemiology, Etiology, and Approaches to Treatment. **2004**, 241-254		1
68	Clinical application of prognostic factors for patients with organic causes of erectile dysfunction on 100 mg of sildenafil citrate. *International Journal of Urology*, **2004**, 11, 1104-9	2.3	5
67	Efficacy of apomorphine and sildenafil in men with nonarteriogenic erectile dysfunction. A comparative crossover study. *Andrologia*, **2004**, 36, 106-10	2.4	26
66	A comparative, crossover study of the efficacy and safety of sildenafil and apomorphine in men with evidence of arteriogenic erectile dysfunction. *International Journal of Impotence Research*, **2004**, 16, 2-7	2.3	34
65	Risk factors in predicting a poor response to sildenafil citrate in elderly men with erectile dysfunction. *BJU International*, **2005**, 95, 366-70	5.6	61
64	Post-marketing surveillance study of the safety and efficacy of sildenafil prescribed in primary care to erectile dysfunction patients. *International Journal of Impotence Research*, **2005**, 17, 71-5	2.3	9
63	The Sexual Health Inventory for Men (SHIM): a 5-year review of research and clinical experience. *International Journal of Impotence Research*, **2005**, 17, 307-19	2.3	266
62	Gene and stem cell therapy for erectile dysfunction. *International Journal of Impotence Research*, **2005**, 17 Suppl 1, S57-63	2.3	23

61	Sildenafil failures may be due to inadequate patient instructions and follow-up: a study on 100 non-responders. *European Urology*, **2005**, 47, 518-22; discussion 522-3	10.2	68
60	Efficacy of sildenafil citrate in men with erectile dysfunction following radical prostatectomy: a systematic review of clinical data. *Journal of Sexual Medicine*, **2005**, 2, 658-67	1.1	75
59	Enhancement of both EDHF and NO/cGMP pathways is necessary to reverse erectile dysfunction in diabetic rats. *Journal of Sexual Medicine*, **2005**, 2, 341-6	1.1	26
58	Drug Insight: oral phosphodiesterase type 5 inhibitors for erectile dysfunction. *Nature Reviews Urology*, **2005**, 2, 239-47		40
57	Efficacy, safety, and treatment satisfaction of tadalafil versus placebo in patients with erectile dysfunction evaluated at tertiary-care academic centers. *Urology*, **2005**, 65, 353-9	1.6	53
56	Does the clinical efficacy of vardenafil correlate with its effect on the endothelial function of cavernosal arteries? A pilot study. *BJU International*, **2006**, 98, 1054-8	5.6	13
55	Outcome analysis of sildenafil citrate for erectile dysfunction of Japanese patients. *International Journal of Impotence Research*, **2006**, 18, 302-5	2.3	5
54	A meta-regression analysis of treatment effect modifiers in trials with flexible-dose oral sildenafil for erectile dysfunction in broad-spectrum populations. *International Journal of Impotence Research* , **2006**, 18, 559-65	2.3	11
53	Can atorvastatin improve the response to sildenafil in men with erectile dysfunction not initially responsive to sildenafil? Hypothesis and pilot trial results. *Journal of Sexual Medicine*, **2006**, 3, 303-8	1.1	64
52	Efficacy of tadalafil in men with erectile dysfunction naïve to phosphodiesterase 5 inhibitor therapy compared with prior responders to sildenafil citrate. *Journal of Sexual Medicine*, **2006**, 3, 668-675	1.1	14
51	Predictors of tadalafil efficacy in men with erectile dysfunction: the SURE study comparing two dosing regimens. *Journal of Sexual Medicine*, **2006**, 3, 1050-1058	1.1	8
50	Can written information material help to increase treatment motivation in patients with erectile dysfunction? A survey of 1188 men. *International Journal of Impotence Research*, **2007**, 19, 330-5	2.3	7
49	Efficient gene expression system using the RTP801 promoter in the corpus cavernosum of high-cholesterol diet-induced erectile dysfunction rats for gene therapy. *Journal of Sexual Medicine*, **2008**, 5, 1355-64	1.1	14
48	The efficacy and safety of udenafil [Zydena] for the treatment of erectile dysfunction in hypertensive men taking concomitant antihypertensive agents. *Journal of Sexual Medicine*, **2009**, 6, 3166-76	1.1	19
47	Phosphodiesterase type 5 inhibitors in postprostatectomy erectile dysfunction: a critical analysis of the basic science rationale and clinical application. *European Urology*, **2009**, 55, 334-47	10.2	124
46	A mouse model of cavernous nerve injury-induced erectile dysfunction: functional and morphological characterization of the corpus cavernosum. *Journal of Sexual Medicine*, **2010**, 7, 3351-64	1.1	40
45	Intracavernous delivery of a designed angiopoietin-1 variant rescues erectile function by enhancing endothelial regeneration in the streptozotocin-induced diabetic mouse. *Diabetes*, **2011**, 60, 969-80	0.9	60
44	Should assessment of penetrative sexual activity be used as the treatment arbiter in the management of Peyronie's disease?. *International Journal of Impotence Research*, **2011**, 23, 70-5	2.3	4

43	Optimizing postoperative sexual function after radical prostatectomy. *Therapeutic Advances in Urology*, **2012**, 4, 347-65	3.2	12
42	Advances in cell-based therapy for peripheral vascular disease. *Atherosclerosis*, **2012**, 223, 269-77	3.1	25
41	Response to on-demand vardenafil was improved by its daily usage in hypertensive men. *Urology*, **2012**, 80, 858-64	1.6	9
40	Intracavernous delivery of freshly isolated stromal vascular fraction rescues erectile function by enhancing endothelial regeneration in the streptozotocin-induced diabetic mouse. *Journal of Sexual Medicine*, **2012**, 9, 3051-65	1.1	27
39	Differential expression of nerve injury-induced protein 1 (ninjurin 1) in in vivo and in vitro models for diabetic erectile dysfunction. *Korean Journal of Urology*, **2012**, 53, 636-42		4
38	Neurotrophic effect of bone marrow mesenchymal stem cells for erectile dysfunction in diabetic rats. *Journal of Developmental and Physical Disabilities*, **2012**, 35, 601-7		57
37	Effect of intracavernous administration of angiopoietin-4 on erectile function in the streptozotocin-induced diabetic mouse. *Journal of Sexual Medicine*, **2013**, 10, 2912-27	1.1	15
36	Nerve injury-induced protein 1 (Ninjurin-1) is a novel therapeutic target for cavernous nerve injury-induced erectile dysfunction in mice. *Journal of Sexual Medicine*, **2013**, 10, 1488-501	1.1	15
35	Xenogenic transplantation of human breast adipose-derived stromal vascular fraction enhances recovery of erectile function in diabetic mice. *Biology of Reproduction*, **2014**, 90, 66	3.9	21
34	Aberrant expression of Wnt family contributes to the pathogenesis of diabetes-induced erectile dysfunction. *Andrology*, **2014**, 2, 107-16	4.2	10
33	Effectiveness of intracavernous delivery of adenovirus encoding Smad7 gene on erectile function in a mouse model of cavernous nerve injury. *Journal of Sexual Medicine*, **2014**, 11, 51-63	1.1	9
32	Intracavernous delivery of clonal mesenchymal stem cells restores erectile function in a mouse model of cavernous nerve injury. *Journal of Sexual Medicine*, **2014**, 11, 411-23	1.1	30
31	Intracavernous delivery of stromal vascular fraction restores erectile function through production of angiogenic factors in a mouse model of cavernous nerve injury. *Journal of Sexual Medicine*, **2014**, 11, 1962-73	1.1	19
30	Inhibition of Ninjurin 1 restores erectile function through dual angiogenic and neurotrophic effects in the diabetic mouse. *Proceedings of the National Academy of Sciences of the United States of America*, **2014**, 111, E2731-40	11.5	41
29	Designed angiopoietin-1 variant, COMP-angiopoietin-1, rescues erectile function through healthy cavernous angiogenesis in a hypercholesterolemic mouse. *Scientific Reports*, **2015**, 5, 9222	4.9	12
28	Role of Schwann cells in the regeneration of penile and peripheral nerves. *Asian Journal of Andrology*, **2015**, 17, 776-82	2.8	29
27	Optimizing in vivo gene transfer into mouse corpus cavernosum by use of surface electroporation. *Korean Journal of Urology*, **2015**, 56, 197-204		2
26	Association Between Dosage Frequency and the Treatment Outcomes of Sildenafil in Young and Middle-aged Men With Erectile Dysfunction: A Chinese, Multicenter, Observational Study. *Urology*, **2015**, 86, 62-7	1.6	2

25	Sexual Dysfunction in Men and Women. **2016**, 785-830		1
24	Sac-1004, a Pseudo-Sugar Derivative of Cholesterol, Restores Erectile Function through Reconstruction of Nonleaky and Functional Cavernous Angiogenesis in the Streptozotocin Induced Diabetic Mouse. *Journal of Urology*, **2016**, 195, 1936-46	2.5	9
23	Intracavernous delivery of clonal mesenchymal stem cells rescues erectile function in the streptozotocin-induced diabetic mouse. *Andrology*, **2016**, 4, 172-84	4.2	21
22	Taurine Supplementation Improves Erectile Function in Rats with Streptozotocin-induced Type 1 Diabetes via Amelioration of Penile Fibrosis and Endothelial Dysfunction. *Journal of Sexual Medicine* , **2016**, 13, 778-85	1.1	23
21	cAMP-dependent post-translational modification of neuronal nitric oxide synthase neuroprotects penile erection in rats. *BJU International*, **2017**, 120, 861-872	5.6	5
20	Penile neurovascular structure revisited: immunohistochemical studies with three-dimensional reconstruction. *Andrology*, **2017**, 5, 964-970	4.2	5
19	Longitudinal changes in erectile function after thulium:YAG prostatectomy for the treatment of benign prostatic obstruction: a 1-year follow-up study. *Lasers in Medical Science*, **2017**, 32, 1517-1523	3.1	3
18	Dickkopf2 rescues erectile function by enhancing penile neurovascular regeneration in a mouse model of cavernous nerve injury. *Scientific Reports*, **2017**, 7, 17819	4.9	5
17	Research in pharmacotherapy for erectile dysfunction. *Translational Andrology and Urology*, **2017**, 6, 207-215	2.3	17
16	PDGF-mediated PI3K/AKT/β-catenin signaling regulates gap junctions in corpus cavernosum smooth muscle cells. *Experimental Cell Research*, **2018**, 362, 252-259	4.2	13
15	Inhibition of proNGF and p75 Pathway Restores Erectile Function Through Dual Angiogenic and Neurotrophic Effects in the Diabetic Mouse. *Journal of Sexual Medicine*, **2019**, 16, 351-364	1.1	7
14	Embryonic stem cell-derived extracellular vesicle-mimetic nanovesicles rescue erectile function by enhancing penile neurovascular regeneration in the streptozotocin-induced diabetic mouse. *Scientific Reports*, **2019**, 9, 20072	4.9	8
13	Intracavernous delivery of Dickkopf3 gene or peptide rescues erectile function through enhanced cavernous angiogenesis in the diabetic mouse. *Andrology*, **2020**, 8, 1387-1397	4.2	1
12	Neutralizing antibody to proNGF rescues erectile function by regulating the expression of neurotrophic and angiogenic factors in a mouse model of cavernous nerve injury. *Andrology*, **2021**, 9, 329-341	4.2	1
11	Extracorporeal shock wave therapy combined with engineered mesenchymal stem cells expressing stromal cell-derived factor-1 can improve erectile dysfunction in streptozotocin-induced diabetic rats. *Translational Andrology and Urology*, **2021**, 10, 2362-2372	2.3	1
10	Sexual Dysfunction in Men and Women. **2011**, 778-816		2
9	Sildenafil in the treatment of erectile dysfunction: an overview of the clinical evidence. *Clinical Interventions in Aging*, **2006**, 1, 403-14	4	36
8	A meta-regression evaluating the effectiveness and prognostic factors of oral phosphodiesterase type 5 inhibitors for the treatment of erectile dysfunction. *Asian Journal of Andrology*, **2016**, 18, 60-5	2.8	3

7	Combination of stromal vascular fraction and gene therapy improves long-term therapeutic efficacy for diabetes-induced erectile dysfunction. *Asian Journal of Andrology*, **2018**, 20, 465-472	2.8	3
6	Erectile dysfunction in the aging man: current options for treatment. *Aging Health*, **2006**, 2, 71-86		0
5	Non-pharmacologic Erectile Dysfunction Treatments After Prostate Cancer Therapy. **2009**, 209-231		0
4	Combined treatment with extracorporeal shockwaves therapy and an herbal formulation for activation of penile progenitor cells and antioxidant activity in diabetic erectile dysfunction. *Translational Andrology and Urology*, **2020**, 9, 416-427	2.3	4
3	[A novel approach to treating erectile dysfunction with a light-controlled nitric oxide donor].. *Folia Pharmacologica Japonica*, **2022**, 157, 172-175	0	
2	Efficacy of Low-Intensity Extracorporeal Shock Wave Treatment in Erectile Dysfunction following Radical Prostatectomy: A Systematic Review and Meta-Analysis. *Journal of Clinical Medicine*, **2022**, 11, 2775	5.1	
1	An update on the current status and future prospects of erectile dysfunction following radical prostatectomy.. *Prostate*, **2022**,	4.2	0